Veliparib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Veliparib
Veliparib skeletal.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • experimental
Identifiers
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.206.770
Chemical and physical data
Formula C13H16N4O
Molar mass 244.29 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Veliparib (ABT-888)[1] is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.[2]

It inhibits both PARP1 and PARP2.[3][4]

Development[edit]

Veliparib is being developed by AbbVie. It was derived from a prior lead compound (A 620223). The FDA awarded orphan drug status in November 2016 for NSCLC.[5]

Clinical trials[edit]

As of 2017, 96 clinical trials involving veliparib had been registered with the FDA.[6] It was included in the I-SPY2 breast cancer trial.[7]

Numerous phase I clinical trials are in progress.[8] Over 40 phase II clinical trials have been registered, for indications such as metastatic melanoma,[9] breast cancer,[10] NSCLC, prostate cancer[11] and brain tumors associated with metastatic primary tumors.

Combination trials have evaluated velibarib in combination with doxorubicin, temozolomide, topotecan, carboplatin, paclitaxel, pemetrexed, cyclophosphamide, gemcitabine, and others.[12]

By June 2014 it was in three phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC).[13]

References[edit]